RecruitingPhase 2NCT06455293

Psilocybin Therapy for Depression in Parkinson's Disease

The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease


Sponsor

Joshua Woolley, MD, PhD

Enrollment

60 participants

Start Date

Aug 19, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.


Eligibility

Min Age: 40 YearsMax Age: 80 Years

Inclusion Criteria6

  • Age 40 to 80
  • Comfortable speaking and writing in English
  • Have neurologist-diagnosed idiopathic Parkinson's disease (PD), Hoehn and Yahr stages 1 to 3 during an "on" phase (time when medication/DBS for parkinsonian motor feature, including bradykinesia and rigidity is in effect)
  • Currently experiencing depressive symptoms
  • Able to attend all in-person visits at UCSF as well as virtual visits
  • Have a primary care provider, neurologist, or psychiatrist who is actively managing or coordinating

Exclusion Criteria4

  • Psychotic symptoms involving loss of insight
  • Significant cognitive impairment
  • Regular use of medications that may have problematic interactions with psilocybin
  • A health condition that makes this study unsafe or unfeasible, determined by study physicians

Interventions

DRUGPsilocybin

Single dose of psilocybin ranging from low ("microdose") to high delivered orally with psychological support and monitoring


Locations(1)

University of California, San Francisco

San Francisco, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06455293


Related Trials